Based on target consumer, GLP-1 Users for Weight Management represent approximately 31.80% share in 2026, driven by the high adoption of GLP-1 agonists specifically for weight loss and the corresponding need for protein, hydration, and micronutrient support
This action can then activate SIRT1 pathways, which are crucial for mitochondrial biogenesis and fat oxidation
Some have hypothesised that rapid weight lossa common effect of semaglutide therapymight alter foot biomechanics or fat pad distribution, potentially contributing to discomfort, though this remains speculative without specific evidence
And any time youve experienced a dose-related adverse event, nausea, vomiting, or dizziness, that was more severe than expected